I'm conscious of the post count's inexorable advance toward the limit, so and I'd like to take the opportunity to say thanks to all for an informative thread.
@Helleofabore:
So I take it Butterfly that you accept the sections of Baker that I copied and pasted that are relevant to the topic of adolescent female transitioners.
I don't think I've ever disputed the relevance or importance of this research. Anything that helps make treatment safer for young people is invaluable.
And if you knew anything, anything at all about the current cohort which I believe you don’t, you would know that the starting point for the teenage females who are trans in this current cohort is very poor and usually combined with comorbidities.
I do! It's well known and documented and I know people going through it right now! I've never disputed this. I agreed with this point in a post back on page 21, saying that Should trans boys be given access to blockers, if they ask for them, after careful evaluation? As a matter of principle, of course my answer should be an unreserved yes - however, I think a measure more leeway can be given here.
...when it comes to a tug of war between the two, it's testosterone that seems to have right of way in terms of permanent, irreversible and distressing effects that are liable to cause harm and lead to negative long term outcomes.
I do think that trans boys have less immediate, devastating pressure to get on an early treatment pathway; testosterone is a vicious body-warping engine of transformation, and -without wanting to minimise their struggles in the slightest, as the monkey's paw definitely curls in other ways- they tend to get an easier ride as late transitioners.
You're arguing against an argument I've never made! I think we agree that today's point of contention is the 2017+ Tanner 2/3 Female-Assigned cohort.
I think I've argued my case (that wholesale banning Blockers for all adolescents isn't the answer) reasonably well, and hopefully dispelled at least some of the fears and myths about long term outcomes (i.e. that we actually have a fair number of datapoints, and we don't hear about them because they're largely happily living their lives trying not to get drawn into the gravitational pull of these debates which can have very negative effects on our mental health).
Right from the start, I was expecting to have to defend my own integrity as a personal datapoint - I'm an outsider jumping in and providing a voice that challenged some of the well-entrenched and picked-over concerns evidenced here. I think it's a little ludicrous that it's been assumed that I haven't been closely following the research. I'm a living part of the research, even if I haven't been cited.
Like many on this forum, I've been following the (sparse) news about research into Blockers quite intently - it's a subject of understandable curiosity to me, and I've often worried about the long term impacts especially for those who enter the treatment process even earlier than I do. I've been reassured by the tentative evidence so far, despite lamenting the new struggles faced, and am horrified by the news of the chronic systemic struggles that GIDS has had to deal with, which have made it extremely difficult to provide the quality of care that patients deserve. Other teams around the world have been better able to withstand the ongoing demands of the Gender Renaissance, and are slowly publishing their findings.
As has been pointed out, this isn't just a problem that GIDS is facing - waiting lists are utterly atrocious across the board, and it can take half a decade to practically arrive at the point of receiving actual treatment for a condition that's come to hang as a miserable blight over one's life. These factors have a massive impact on the integrity of research, as the treatment pathway extends well beyond the realm of endocrine interventions. I know the lack of ability to access surgery throughout my early twenties had a huge effect on my own mental health, which would have impacted on any followup studies that were performed. I know also that the vicious social attitudes of the time -which sadly are still a factor- contributed to a hugely negative effect on my own levels of anxiety - I've quoted hypervigilance and a constant baseline need to keep others at arm's reach for my own protection.
I'd like to give a bit of a reality check on the results of the quality of life and mental health studies that involve blockers as part of a treatment pathway; the numbers involved and the conclusions drawn from them can be a little abstract and detached from the personal aspect. I've also noticed that the goalposts keep shifting in these kinds of discussions when it comes to evidence.
We start with 'transitioning is an inherently harmful erasure of the GNC behaviour we used to know, love and build entire communities around when there weren't healthcare provisions in place; we should teach people to love and accept their bodies and stop subdividing themselves up into unhelpful identities. Nobody should transition.' This is a viewpoint regularly expressed by some posters on this thread. I actually find this a hugely compelling philosophical stance on the entire concept of attempting to modify our bodies to align with societal expectations, and when argued from the perspective of non-trans people trying to protect people they don't consider to be trans, it has a great deal of merit. However:
When demonstrated that there are cohorts of people for whom expressing GNC behaviours and presentations are insufficient to address gender dysphoria and for whom transitioning seems to be the only treatment that tips the cost/benefit scales favourably, the argument shifts. 'Ok maybe it might help some people; perhaps there is a clinical need in some cases - but how do you know who will benefit? How do we know who is 'genuine' and who is just confused? A lot of kids are confused and distressed during puberty but they don't grow up to be trans, do they?'
In sympathy of this thorny issue, psychiatric clinicians have developed a systematic evaluation system over several decades of revision and iteration to create a cost/benefit suitability metric for protecting against harm and providing a case for hormonal and surgical intervention. It isn't perfect, but it seems to at least serve as some kind of guide. The goalposts change. The stance becomes 'people are being tricked by the medical establishment into believing that transgenderism is a medical condition and that the only way to be happy is to transition! We have no proof that transition makes people with GD happier; doctors are just putting words into their mouths so they can claim success in their experiments and Big Pharma can make lifelong patients out of them'.
When studies are conducted that report high rates of happiness over transitioning many years after the fact, and the abject failure of conversion therapy, it becomes 'you can't trust people to self-report their own happiness; the methodology of these studies is questionable. Only evaluation by psychiatric clinicians can really prove people are actually happy.'
When followup studies on transitioners are conducted by psychiatric clinicians, and similarly find positive outcomes, it becomes 'ok maybe transitioning is able to make some adults happy. They aren't really happy of course - they still show heightened anxiety and depression in comparison with the rest of the population, and some of them regret having GRS.'
When it's pointed out that gender dysphoria is an ongoing issue that carries its physical and psychological scars forward throughout and out the other side of transition; that it's hard living in a transphobic world that grew up on using trans people as the punchline to a joke and debates your right to exist and hurts you when it recognises you as 'other' causes anxiety and depression; where being unable or unwilling to have surgery yet due to waiting lists or worries about outcomes carries its own psychological load, and where ghoulish cadres of online trolls maintain libraries of undesirable surgical outcomes in order to torment and harass trans people and 'prove' to them that their surgeries are imperfect (we know, we're sad about it, we'll live with it): we go right back to 'well that's proof that nobody should transition as it'll only make them sad, then.'
When a compromise technique is developed to help 16+ people (who have been established as meeting the diagnostic criteria and are deemed likely to transition in adulthood anyway) from avoiding the unwanted effects of puberty so they can avoid the worst of their gender dysphoria and have a better chance of escaping transphobia in adulthood, it becomes 'This is an off-label use of a poorly researched experimental drug! They can't consent! They should have to wait until they're 18!'
When initial studies are provided showing that transitioning actually seems to work for appropriate adolescents in the 16+ cohort, and a tiny generation of trans people silently grows up and disappears off to live their lives while a few brave individuals stick around and open themselves up to public scrutiny, it becomes 'You have no evidence of positive outcomes! What about side effects? What about long-term damage? You're transing kids, reinforcing the gender binary and setting them up for a lifetime of medicalisation!'
When evidence of positive outcomes is provided, which still reflect the heightened anxiety and bleakness of living with a miserable secret past in a society that hates you but sometimes doesn't know it yet, it becomes: 'These results are inconclusive and the sample sizes are small! There are confounding factors!'
Yes. There are. It's still hard to be trans even if you don't get beaten up for walking to the shops anymore. You're still infertile. You're still on lifelong medication. These are miserable things, but we respectfully assert our agency in being able to choose to endure them, as we are all too aware that the alternative is worse. When we point this out, the argument becomes 'It's duplicitous and cowardly anyway. People should be open and proud about being trans. They should challenge restrictive and outdated notions of gendered expression. Why are you in such a desperate scramble to conform to society's expectations?' sigh aaand we're right back to the beginning again. We medically transitioned because conforming to society's expectations demonstrably wasn't alleviating gender dysphoria, and nor was simply socially transitioning and/or not conforming. There was something else there; another axis on our graphs.
When clinicians move to treating earlier stages of puberty in order to improve both immediate and long-term dysphoria-reducing effects and address some of the confounding factors, the goalposts shift again. 'It is unproven at this younger age range! There will be permanent side effects! Gillick competence can't apply in the case of gender dysphoria! There are co-morbidities!'.
All good points, worthy of sober consideration and great care. So this protocol has been in effect for nearly a decade in the Netherlands, and not long after in other places. Time alone doesn't convey authority, of course, but reports show that while there are some (expected) complex negative and irreversible side effects from wholesale delaying puberty, none of them seem to be absolute show-stoppers, many of them are rendered irrelevant by later/adjusted surgical or hormonal interventions, and as always, it's up to clinicians to work closely with the individual on a case by case basis to decide what works for them. This is the protocol that GIDS tries to follow, but logistical constraints mean that patients who come to them have been waiting 2+ years for their first appointment already (nowadays it's 3+)
Meanwhile, Gillick competence has been tested to the limit in the UK in a landmark case and, while it evidently has huge flaws, GIDS is eventually found to be acting within the law in prescribing blockers to under-16's (the tiny proportion who even get that far), sadly obstructing a year's worth of kids who actually managed to get their way through the waiting lists in the process.
The goalposts have now shifted again, becoming: 'Ok so maybe it's ok - though difficult and complicated - for assigned-male patients. What about the recent extremely young female-assigned cohort that has seen a significant increase in numbers? And a small but growing number of prominent detransitioners? Isn't this evidence of so-called ROGD/social contagion?'
That's where you're arguing from now, @Helleofabore. And I think it's a good point. There are unanswered questions.